GFC Life Science Co., Ltd Stock: price and insider trades · South Korea

GFC Life Science Co., Ltd, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). From 6 November 2025 to 6 November 2026, the disclosure feed for GFC Life Science Co., Ltd logged 23 filings by 5 insiders.

No insider sold shares on the market over the period. Instead, the filings list 21 purchases totalling €2.0M, made by 4 insiders. The totals do not cover 12 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €1.7M from 비엔비자산운용, disclosed on 9 March 2026, or 9.8% of market capitalisation. Those buying include 1 major shareholder, 1 board member and 1 senior executive.

Compared with its exchange (2,657 companies, median 7 filings), a count of 23 filings is above the norm. Our records for GFC Life Science Co., Ltd go back to 2022, with 33 purchases and 4 sales on the open market in total.

The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (6 November 2026) now reads 3 days. Typically, a trade is published a median of 4 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.